InvestSMART

Noxopharm Limited (ASX:NOX)

ALERT: Price-sensitive ASX Announcement for NOX
Current share price for NOX : $0.061 0.001 (1.67%)+
Announcement
Release
26 May 2026 8:21AM
Price at Release
$0.060
Full Release
download
Summary
Noxopharm Limited, an Australian clinical-stage biotech company, has released promising new data on its Sofra technology platform, which demonstrates significant cancer-fighting potential by enhancing the activity of Toll-like receptor 8 (TLR8). The company has developed proprietary oligonucleotides that bolster TLR8 activity far beyond current clinical-stage drugs, offering a powerful new approach when combined with standard cancer therapies like chemotherapy. With the potential for broad applications in autoimmune diseases and RNA therapeutics, the Sofra platform, protected by a US patent, positions Noxopharm as a competitive player in the growing global cancer treatment market. The latest research results indicate a potential 200-fold increase in immune activation in human models, paving the way for further testing in humanized mice and diverse cancer models.
Key Points
  • Noxopharm Limited announces new data confirming the cancer-fighting potential of its Sofra technology.
  • The company focuses on leveraging Toll-like receptor 8 (TLR8) for cancer treatment.
  • Noxopharm has developed oligonucleotides that enhance TLR8 activity beyond current drugs.
  • The new approach combines TLR8 activation with standard cancer therapies like chemotherapy.
  • The technology is protected by a US patent and shows promise for competitive cancer treatment.
  • Experimental results show significant amplification of TLR8 activity in human and animal models.
  • The company aims to expand testing in humanized mice and various cancer models.
  • Sofra technology has applications in autoimmune diseases and RNA therapeutics.
  • Noxopharm is an Australian biotech company focusing on cancer and inflammation treatments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.